Author

D. P. Pinto

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. C. Ferreira· 1 shared A. S. Carlos· 1 shared C. Q. Sacramento· 1 shared G. P. E. da Silveira· 1 shared H. C. Castro-Faria-Neto· 1 shared H. M. Pereira· 1 shared J. d. C. P. d'Avila· 1 shared J. P. B. Viola· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. C. Ferreira

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo

O. A. Chaves, C. Q. Sacramento, A. C. Ferreira, M. Mattos, N. Fintelman-Rodrigues, J. R. Temerozo, D. P. Pinto, G. P. E. da Silveira, L. B. da Fonseca, H. M. Pereira, A. S. Carlos, J. d. C. P. d'Avila, J. P. B. Viola, R. Q. Monteiro, L. Vazquez, , T. M. L. Souza

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

bioRxiv · Nov 24, 2021Pharmacology & Toxicology